drug

(fosnetupitant chloride hydrochloride + palonosetron hydrochloride)

Marketedupdated 6mo ago

by Helsinn Therapeutics (US) Inc

Approved

community read0 votes

all catalysts(0)

nothing on the calendar yet

Trials studying (fosnetupitant chloride hydrochloride + palonosetron hydrochloride)

phase1A Clinical Trial to Assess Safety and Pharmacokinetics of Fosnetupitant 235 mg and Metabolites in Healthy Volunteersterminatedn=50
phase2Prevention of Breakthrough CINV in Patients Receiving Moderately or Highly Emetogenic Chemotherapyunknownn=100

Patent cliff

source: FDA Orange Book

first barrier falls

Nov 18, 2030

~4.1 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (36)

Jun 2, 2037formulationUS 10624911
Jun 2, 2037formulationUS 10624911
Jun 2, 2037formulationUS 11529362
Jun 2, 2037formulationUS 11529362
Jun 2, 2037formulationUS 12208109
Jun 2, 2037formulationUS 12208109
Sep 25, 2035compositionUS 10233154
Sep 25, 2035compositionUS 10676440
Sep 25, 2035compositionUS 10961195
Sep 25, 2035compositionUS 9951016
May 23, 2032method-of-use (U-2301)US 10208073
May 23, 2032method-of-use (U-2301)US 10208073
May 23, 2032compositionUS 10717721
May 23, 2032compositionUS 10717721
May 23, 2032compositionUS 11312698
May 23, 2032compositionUS 11312698
May 23, 2032compositionUS 8426450
May 23, 2032compositionUS 8426450
May 23, 2032method-of-use (U-2301)US 8895586
May 23, 2032method-of-use (U-2301)US 8895586
May 23, 2032compositionUS 9403772
May 23, 2032compositionUS 9403772
May 23, 2032compositionUS 9908907
May 23, 2032compositionUS 9908907
Sep 9, 2031method-of-use (U-2293)US 92719754.9y
Dec 17, 2030method-of-use (U-2301)US 108282974.1y
Dec 17, 2030method-of-use (U-2293)US 108282974.1y
Dec 17, 2030method-of-use (U-2301)US 108282974.1y
Nov 18, 2030formulationUS 115595234.1y
Nov 18, 2030formulationUS 120424944.1y
Nov 18, 2030method-of-use (U-2293)US 86238264.1y
Nov 18, 2030formulationUS 89519694.1y
Nov 18, 2030method-of-use (U-2293)US 91863574.1y
Nov 18, 2030method-of-use (U-2301)US 91863574.1y
Nov 18, 2030method-of-use (U-2301)US 91863574.1y
Nov 18, 2030method-of-use (U-2293)US 99435154.1y

News(0)

no news has mentioned this drug yet

Data sources

ClinicalTrials.gov

last refreshed 1h ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug

save

(fosnetupitant chloride hydrochloride + palonosetron hydrochloride)

Marketedupdated 6mo ago

by Helsinn Therapeutics (US) Inc

Approved

community read0 votes

all catalysts(0)

nothing on the calendar yet

Trials studying (fosnetupitant chloride hydrochloride + palonosetron hydrochloride)

phase1A Clinical Trial to Assess Safety and Pharmacokinetics of Fosnetupitant 235 mg and Metabolites in Healthy Volunteersterminatedn=50
phase2Prevention of Breakthrough CINV in Patients Receiving Moderately or Highly Emetogenic Chemotherapyunknownn=100

Patent cliff

source: FDA Orange Book

first barrier falls

Nov 18, 2030

~4.1 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (36)

Jun 2, 2037formulationUS 10624911
Jun 2, 2037formulationUS 10624911
Jun 2, 2037formulationUS 11529362
Jun 2, 2037formulationUS 11529362
Jun 2, 2037formulationUS 12208109
Jun 2, 2037formulationUS 12208109
Sep 25, 2035compositionUS 10233154
Sep 25, 2035compositionUS 10676440
Sep 25, 2035compositionUS 10961195
Sep 25, 2035compositionUS 9951016
May 23, 2032method-of-use (U-2301)US 10208073
May 23, 2032method-of-use (U-2301)US 10208073
May 23, 2032compositionUS 10717721
May 23, 2032compositionUS 10717721
May 23, 2032compositionUS 11312698
May 23, 2032compositionUS 11312698
May 23, 2032compositionUS 8426450
May 23, 2032compositionUS 8426450
May 23, 2032method-of-use (U-2301)US 8895586
May 23, 2032method-of-use (U-2301)US 8895586
May 23, 2032compositionUS 9403772
May 23, 2032compositionUS 9403772
May 23, 2032compositionUS 9908907
May 23, 2032compositionUS 9908907
Sep 9, 2031method-of-use (U-2293)US 92719754.9y
Dec 17, 2030method-of-use (U-2301)US 108282974.1y
Dec 17, 2030method-of-use (U-2293)US 108282974.1y
Dec 17, 2030method-of-use (U-2301)US 108282974.1y
Nov 18, 2030formulationUS 115595234.1y
Nov 18, 2030formulationUS 120424944.1y
Nov 18, 2030method-of-use (U-2293)US 86238264.1y
Nov 18, 2030formulationUS 89519694.1y
Nov 18, 2030method-of-use (U-2293)US 91863574.1y
Nov 18, 2030method-of-use (U-2301)US 91863574.1y
Nov 18, 2030method-of-use (U-2301)US 91863574.1y
Nov 18, 2030method-of-use (U-2293)US 99435154.1y

News(0)

no news has mentioned this drug yet

Data sources

ClinicalTrials.gov

last refreshed 1h ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

(fosnetupitant chloride hydrochloride + palonosetron hydrochloride)

all catalysts(0)

Trials studying (fosnetupitant chloride hydrochloride + palonosetron hydrochloride)

Patent cliff

patents (36)

News(0)

Report a data issue

comments(0)

(fosnetupitant chloride hydrochloride + palonosetron hydrochloride)

all catalysts(0)

Trials studying (fosnetupitant chloride hydrochloride + palonosetron hydrochloride)

Patent cliff

patents (36)

News(0)

Report a data issue

comments(0)